RxDoctor Payments Data

Shari Wilson

Family · Lake Jackson, TXNPI 1629602354

Payments from drug & device makers

$3,341in general payments, 2019–2025

Across 46 payments — averaging $72.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$2K
  • AstraZeneca$263
  • Novo Nordisk$253
  • Boston Scientific$174
  • Smith+Nephew$91
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$75
  • plus $189 from 6 others

What the payments were for

  • Travel & lodging$1,56747%
  • Food & beverage$1,77553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,341 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$2,680,234
Medicare patients
67
Services billed
1,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$18,715
TrulicityDulaglutide11$11,021
EliquisApixaban19$10,686
Gabapentin33$412
Atorvastatin Calcium26$321
Losartan Potassium20$211
Tamsulosin Hcl11$204
Albuterol Sulfate HfaAlbuterol Sulfate13$159
Furosemide27$141
Metoprolol Succinate11$130
Lisinopril16$117
Escitalopram Oxalate15$103
Montelukast Sodium16$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$253$18,71512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Lake Jackson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →